Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Rhea-AI Summary
Atossa Therapeutics (Nasdaq: ATOS) on March 19, 2026 added two senior clinical leaders: Kathy Puyana Theall, M.D. as Medical Director - Breast Oncology and Adebola Giwa, M.D. as Medical Director - Rare Diseases.
These hires bolster development of (Z)-Endoxifen across breast cancer and rare disease programs, including McCune-Albright syndrome and Duchenne muscular dystrophy, and bring regulatory and global trial experience to support upcoming clinical and regulatory milestones.
Positive
- Added two senior clinical hires on March 19, 2026
- Kathy Theall brings late-stage breast cancer and FDA approval experience (elacestrant, 2023)
- Adebola Giwa brings pediatric endocrine and global rare-disease development experience
- Hires directly support advancement of (Z)-Endoxifen in breast cancer, MAS, and DMD programs
Negative
- No specific clinical timelines or enrollment targets provided for the (Z)-Endoxifen programs
- No financial details disclosed regarding hiring costs or incremental R&D budget impact
Key Figures
Market Reality Check
Peers on Argus
ATOS was down 6.92% while several biotech peers also fell (e.g., PYXS -4.97%, SPRO -4.65%, MGNX -2.61%, ANRO -0.62%) and ADAG gained 0.77%, indicating mixed but generally weak sector action rather than a clear group move tied to this news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Preclinical data update | Positive | +5.7% | Presented preclinical (Z)-endoxifen data in DMD showing functional and biomarker benefits. |
| Feb 11 | Shareholder letter | Positive | -16.0% | Outlined 2025 progress, 2026 plans, regulatory feedback, designations, cash and reverse split. |
| Feb 05 | Strategy reaffirmation | Positive | +0.8% | Reaffirmed DMD market position and PRV opportunity after program reauthorization. |
| Jan 21 | Leadership recognition | Positive | +0.1% | CEO named top healthcare technology leader tied to (Z)-endoxifen progress. |
| Jan 16 | Orphan designation | Positive | -1.9% | Received FDA Orphan Drug Designation for (Z)-endoxifen in DMD. |
Recent ATOS news has produced mixed reactions: some positive regulatory and clinical updates aligned with modest gains, while other favorable milestones, including designations and strategic letters, coincided with declines.
Over the last few months, ATOS has focused on advancing (Z)-endoxifen across oncology and Duchenne muscular dystrophy. Key events include Orphan Drug Designation for DMD on Jan 16, 2026, CEO recognition tied to multiple Phase 2 efforts on Jan 21, 2026, and reaffirmation of its DMD strategy with Priority Review Voucher prospects on Feb 5, 2026. A detailed shareholder letter on Feb 11, 2026 and new preclinical DMD data on Mar 12, 2026 underline a pipeline‑building trajectory that this leadership expansion supports.
Market Pulse Summary
This announcement highlights Atossa’s effort to reinforce its clinical organization by adding seasoned leaders in breast oncology and rare diseases to support (Z)-endoxifen programs, including DMD and McCune‑Albright syndrome. Set against recent milestones such as Orphan Drug Designation and new preclinical data, it underscores a build‑out phase. Investors may watch for subsequent clinical trial initiations, regulatory interactions, and data readouts to assess the impact of these appointments.
Key Terms
duchenne muscular dystrophy medical
metastatic breast cancer medical
nephrology medical
clinical development technical
regulatory approvals regulatory
AI-generated analysis. Not financial advice.
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's pipeline
"These additions reflect our continued investment in building a world-class clinical organization as we advance our pipeline," said Dr. Steven Quay, Atossa Therapeutics Chief Executive Officer. "Kathy brings a proven track record in late-stage oncology development and regulatory approvals in breast cancer, while Adebola contributes deep expertise in endocrine and rare disease clinical development, with extensive experience advancing innovative therapies from early clinical stages through global execution. Together, they significantly enhance our ability to efficiently advance our programs and deliver meaningful outcomes for patients."
Kathy Puyana Theall, M.D.
Dr. Theall is a board-certified medical oncologist with more than 24 years of experience spanning academic medicine and the biopharmaceutical industry, including over a decade in senior clinical development roles. She brings deep expertise in breast cancer drug development and has contributed to programs supporting multiple global regulatory approvals.
Most recently, Dr. Theall served as Vice President of Clinical Development – Breast Cancer at Stemline-Menarini, where she led clinical strategy and execution supporting the FDA approval of ORSERDU™ (elacestrant) in 2023 and subsequent global approvals. She also led multiple clinical trials, including the Phase Ib/II ELEVATE umbrella study evaluating combination therapies in advanced breast cancer.
Previously, Dr. Theall held senior roles at Pfizer Inc., where she contributed to the clinical development of IBRANCE® (palbociclib), including the PALOMA trials that supported both accelerated and full approvals. She began her career in academic medicine, serving in leadership roles at Tufts Medical Center and as a clinical investigator across more than 40 oncology studies.
"Atossa is at an important stage of growth," said Dr. Theall. "The company's commitment to advancing innovative therapies in breast cancer strongly aligns with my experience and passion, and I look forward to contributing to the continued development of its pipeline."
Adebola Giwa, M.D.
Dr. Giwa is a board-certified pediatrician who trained in pediatric endocrinology at Johns Hopkins and later served on the faculty. He is a physician–scientist and clinical development leader with more than 15 years of experience across academic medicine and the biopharmaceutical industry and brings deep expertise in endocrine, musculoskeletal, and rare disease drug development. He has led the strategy and execution of global clinical programs across multiple therapeutic areas, including endocrinology, musculoskeletal disorders, and nephrology
Most recently, Dr. Giwa served as Senior Medical Director at Maze Therapeutics, where was the primary clinical lead for a genetic chronic kidney disease program and additional early-stage assets, with responsibility for overall clinical strategy, global trial design, safety oversight, and regulatory positioning. He played a key role in portfolio prioritization and executive decision making and led clinical execution across
Prior to Maze, Dr. Giwa was Medical Director at Angitia Biopharma, where he led a global Phase 1 program and advanced the asset into Phase 2, and earlier served at Ascendis Pharma, where he managed multiple global clinical trials across Phase 1 through Phase 3 development.
Dr. Giwa has extensive experience as a medical monitor and clinical lead, with deep involvement in protocol design, regulatory interactions, data monitoring committees, and cross-functional program leadership. He is also the founder of AdeBolus Medical Consulting, where he advises biopharma companies on clinical and translational strategy.
"I'm excited to join Atossa and contribute to the advancement of its clinical programs," said Dr. Giwa. "The opportunity to help develop innovative therapies for patients with significant unmet medical needs is incredibly meaningful, and I look forward to working with the team to advance the company's pipeline and deliver high-quality clinical data to bring new treatments forward."
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-Endoxifen, is currently in development across several clinical settings. More information is available at https://atossatherapeutics.com.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to, our expectations regarding the Company's development and regulatory strategy and related milestones, the potential indications that the Company may pursue for (Z)-Endoxifen, the potential for (Z)-Endoxifen to receive regulatory approval and the timing thereof, expectations regarding the design, enrollment, data, timing, results and outcomes of the Company's clinical studies, and the potential market and growth opportunities for the Company. Words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: our ability to successfully execute our strategy to shorten our clinical development timelines for oncology indications, DMD indication, or other indications for our lead program, (Z)-Endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa's filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-strengthens-clinical-leadership-team-with-the-addition-of-two-experienced-biopharma-executives-302718250.html
SOURCE Atossa Therapeutics Inc
FAQ
Who did Atossa (ATOS) hire on March 19, 2026 and what roles did they take?
How do the March 19, 2026 hires affect Atossa's (Z)-Endoxifen clinical programs?
What experience does Kathy Puyana Theall bring to Atossa (ATOS)?
What expertise does Adebola Giwa bring to Atossa (ATOS) for rare disease work?
Did Atossa (ATOS) disclose timelines or financial details tied to these March 19, 2026 hires?
